Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study

European Neurology

Volumn 72, Issue , 2014, Pages 173-180

  Gajofatto, Alberto ^a,b   Bianchi, Maria Rachele ^a,b   Deotto, Luciano ^b   Benedetti, Maria Donata ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Fingolimod; Multiple sclerosis; Natalizumab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; IMMUNOGLOBULIN; LIVER ENZYME; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; ENZYME BLOOD LEVEL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; HEART PALPITATION; HERPES LABIALIS; HUMAN; HYPERTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION; LEG EDEMA; LEUKOPENIA; LYMPHOCYTOPENIA; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MIDDLE AGED; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RELAPSE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOMITING; ANALOGS AND DERIVATIVES; BRAIN; CLINICAL TRIAL; KAPLAN MEIER METHOD; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; PROPYLENE GLYCOLS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; TREATMENT OUTCOME;

EID: 84910096971     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000361044     Document Type: Article

References (26)

1. Rudick RA, Stuart WH, Calabresi PA, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
2. Cohen JA, Barkhof F, Comi G, et al: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
3. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
4. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
5. Comi G, Kappos L, Palace J, et al: Cardiac safety of fingolimod 0.5 mg during the first dose observation in 4-month, open-label, multi-center FIRST study in patients with relapsing MS. Neurology 2012; 78:S41.003.
6. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
7. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
8. Tubridy N, Behan PO, Capildeo R, et al: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472.
9. Miller DH, Khan OA, Sheremata WA, et al: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
10. Polman CH, O'Connor PW, Havrdova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
11. Rudick RA, Stuart WH, Calabresi PA, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
12. Bloomgren G, Richman S, Hotermans C, et al: Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
13. http://www.biogenidec-international.com/tysabri.aspx?ID=4698 (accessed February 8, 2014).
14. Kappos L, Radue EW, O'Connor P, et al: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
15. Cohen JA, Barkhof F, Comi G, et al: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.
16. Centonze D, Rossi S, Rinaldi F, Gallo P: Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology 2012; 79: 2004-2005.
17. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P: Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012; 18: 1640-1643.
18. Daelman L, Maitrot A, Maarouf A, Chaunu MP, Papeix C, Tourbah A: Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 2012; 18: 1647-1649.
19. Jander S, Turowski B, Kieseier BC, Hartung HP: Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012; 18: 1650-1652.
20. Sempere AP, Martín-Medina P, Berenguer-Ruiz L, et al: Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand 2013; 128:e6-e10 .
21. Laroni A, Brogi D, Milesi V, Abate L, Uccelli A, Mancardi G: Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Mult Scler 2012;19:1236-1237.
22. Havla J, Tackenberg B, Hellwig K, et al: Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol 2013; 260: 1382-1387.
23. de Seze J, Ongagna JC, Collongues N, et al: Reduction of the washout time between natalizumab and fingolimod. Mult Scler 2013; 19:1248.
24. O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M: Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011; 14: 617-627.
25. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A: Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Eur J Clin Pharmacol 2012; 68: 441-448.
26. Braune S, Lang M, Bergmann A; NTC Study Group: Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort. J Neurol 2013;260:2981-2985, Epub ahead of print.